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for by differences in bodyweight and concomitant use of inducer AEDs.
Since the identified covariates had a modest influence on pharmacoki-
netic parameters, BRV is deemed to have a highly predictable exposure in
individual subjects. Results suggest that no dose adjustment is required.
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LEVETIRACETAM, A NEW OPTION TREATMENT FOR
CREUTZFELDT-JACOB DISEASE
Ornella Daniele1, B. Fierro1, M. D’Amelio1, L. Urso1, G. Savecchieri1,
F. Piccoli1, M. R. Tata2 and E. Natale`3 (1Department of Neurology,
University of Palermo, Palermo, Italy; 2Department of Neurology, Uni-
versity of Napoli, Napoli, Italy and 3Department of Neurology, Civil
Hospital, Palermo, Italy)
Rationale: Levetiracetam showed to be effective in the treatment of
myoclonic seizures. The aim of this study is to evaluate the efficacy of
levetiracetam (LEV) in the treatment of myoclonus in Creutzfeldt-Jacob
disease (CJD).
Methods: Since 2003 we treated with LEV 6 patients with CJD who
presented, initially or during the course of the disease, mild, moderate
or intense myoclonus involving subcontinuously face and arms.
Patients were three men (mean age at onset 56 yrs) and three women
(mean age at onset 61 yrs).
Three patients had a sporadic and three a genetic form of CJD. Five
patients had a polymorphism at codon 129 Met/Met and only one had
no polymorphism but showed E200K gene mutation of PRP.
EEG showed in two cases periodic slow waves complex, in two frontal
intermittent rythmic delta activity and in two diffuse, asymmetrical theta.
MRI showed in 4 cases caudate and lenticular hyperintensity and 2 dif-
fuse cerebral atrophy.
LEV was administered at doses of 2000–3000 mg/daily with low titra-
tion. Treatment lasted 3–6 months. At present, only one patients is still
alive; the survival of dead ones was 2–12 months.
Results: All patients showed during treatment, a marked reduction
of myoclonus from moderate intense to mild form; some patients were
myoclonus-free during part of the day.
Conclusions: Initially or during the course of CJD, approximately
90% of patients present movement disorders, especially generalised my-
oclonus. Many drugs have been used in the treatment, including pred-
nisone, levodopa, haloperidol, benzodiazepines and anticonvulsants. On
the basis of our results, we can recommend LEV as a safe and effective
treatment of myoclonus in CJD.
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EVALUATION OF THE PHARMACOKINETIC INTERACTION
OF BRIVARACETAM ON OTHER ANTIEPILEPTIC DRUGS IN
ADULTS WITH PARTIAL-ONSET SEIZURES
C. Otoul, P. von Rosenstiel and A. Stockis (UCB Pharma SA, Braine-
l’Alleud, Belgium)
Rationale: To assess the effect of brivaracetam (BRV) adjunc-
tive treatment on steady-state plasma concentrations of concomitant
antiepileptic drugs (AEDs) in adult patients.
Methods: Patients with refractory epilepsy received oral BRV (5, 20,
50, or 150 mg/day) or placebo BID during 7 to 10 week in 2 double-blind,
placebo-controlled, parallel-group, dose-ranging studies in adjunctive
treatment of partial-onset seizures.
At baseline and during treatment with either add-on BRV or placebo,
AED plasma concentrations (carbamazepine [CBZ] and its epoxide
[CBZ-E], lamotrigine [LTG], levetiracetam [LEV], 10-hydroxy oxcar-
bazepine [OXC], phenytoin [PHT], topiramate [TPM] and valproate
[VPA]) were determined during clinical visits. Data were analysed us-
ing repeated measures covariance analysis with baseline as covariate,
following logarithmic transformation. Pharmacokinetic interaction was
evaluated using the bioequivalence approach (90% confidence intervals
[CI] of the geometric mean concentrations ratios relative to the baseline).
Results: Approximately 70% of 343 patients (51% female; age range
16–65 years), received BRV in addition to 1 or 2 concomitant AEDs
(CBZ 41%, LTG 27%, VPA 19%, LEV 18%, OXC 15%, PHT 14%,
TPM 13%). Mean plasma concentrations (CV = coefficient of variation)
varied from baseline to BRV treatment period as follows: CBZ 8.8 to
8.5 µg/mL (CV = 40%), CBZ-E 1.8 to 2.5 µg/mL (CV = 53%), LEV
36.3 to 40.2 µg/mL (CV = 48%), LTG 5.8 to 6.2 µg/mL (CV = 81%),
OXC 20.5 to 20.3 µg/mL (CV = 41%), PHT 8.6 to 10.7 µg/mL (CV =
75%), TPM 7.4 to 7.5 µg/mL (CV = 74%), VPA 73 to 72 µg/mL (CV =
45%). The geometric mean ratio of concentrations (BRV vs. baseline)
was centered around 100% for CBZ, LEV, LTG, OXC, TPM and VPA
and CI’s were within the 80–125% limits of bioequivalence. No BRV
dose-related trend was observed for these AEDs. For CBZ-E, a moderate
increase was observed at the highest dose. The mean CBZ-E/CBZ ratio
was 0.23, 0.24, 0.26, 0.29 and 0.38 for placebo and BRV 5, 20, 50 and
150 mg/day, respectively. Mean PHT plasma concentrations ratios over
baseline were approximately 25% higher in patients receiving BRV 20
and 50 mg/day (no PHT patient at 150 mg/day) than in the placebo group,
but there was no dose-related trend and numbers of patients were small
(10 to 13 patients per dose).
Conclusions: BRV 5–150 mg/day did not appear to modify the steady-
state plasma concentrations of concomitantly administered CBZ, LTG,
LEV, OXC, TPM and VPA in adult patients with partial-onset seizures.
CBZ-E was modestly increased at the highest dose. The potential ef-
fect on PHT was equivocal. Results suggest that no dose adjustment of
any of these AEDs is required when BRV 5–150 mg/day is added to
combination therapy.
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SINGLE- AND MULTIPLE-DOSE BIOEQUIVALENCE AND
FOOD EFFECT COMPARISON BETWEEN LEVETIRACETAM
EXTENDED RELEASE TABLETS ONCE DAILY AND LEV-
ETIRACETAM IMMEDIATE RELEASE TABLETS TWICE
DAILY IN HEALTHY SUBJECTS
E. Rouits1, I. Burton2, E. Gue´nole´3, M. Troenaru1, S. Bendahmane1
and M. L. Sargentini-Maier1 (1UCB Pharma, Braine-l’Alleud, Belgium;
2SGS Life Science Services, Wavre, Belgium and 3Therapharm, Caen,
France)
Rationale: To compare the bioavailability of a new extended release
levetiracetam 500 mg tablet (LEV XR) given once daily (OD) with that
of levetiracetam 500 mg immediate release tablet (LEV IR; Kepprar)
given twice daily (BID); to assess the effect of food on LEV XR.
Methods: 24 healthy subjects (12M/12F) were randomised in this
open-label, 3-way Latin square cross-over study. Under fasting condi-
tions, 500 mg LEV IR BID or 2 x 500 mg LEV XR OD was administered
on day 1 and from days 3 to 9. Plasma LEV concentration was determined
serially on days 1 and 9. A single dose of 2 x 500 mg LEV XR was ad-
ministered in the third treatment arm with a standard high-fat breakfast.
Bioequivalence or lack of food effect was concluded if the 90% con-
fidence intervals (CIs) of the pairwise adjusted geometric means ratios
(XR/IR or fed/fasted) were entirely contained within 80–125% limits for
Cmax, AUC(0−t) and AUC, and for Cmax and AUC(0–24) at steady-state.
Results: Under fasting conditions, the time to peak was delayed by
approximately 3 h with LEV XR (4 h vs. 0.9 h). CIs for comparisons of
Cmax, AUC(0−t) and AUC ratios after single dosing were all within the
bioequivalence limits. The steady-state AUC(0–24) ratios were also within
the acceptance range. The average steady-state plasma concentration
(Css,av)) was 12.9 µg/mL (13 CV%) and 13.6 µg/mL (16 CV%) for
the XR and IR tablets, respectively. The time during which the LEV
concentration remained ≥75% of Cmax was 7.8 h (27 CV%) vs. 3.4 h (67
CV%). The peak-to-trough fluctuation ratio (PTF) was 1.19 (12 CV%)
vs. 1.27 (22%). When LEV XR was taken with a high-fat meal, the time
to peak was delayed, but the Cmax) and AUC ratios remained within
the bioequivalence limits. Drug-related adverse events (AEs), mostly of
mild intensity, were reported by 13 (54%) and 17 (71%) subjects on LEV
XR and LEV IR, respectively. The type and incidence of AEs following
LEV XR did not differ from LEV’s known tolerability profile. All AEs
resolved at the end of the study.
Conclusions: The new LEV XR 500 mg tablet given OD is bioequiv-
alent to the LEV IR tablet (Kepprar) given BID and its absorption is
not modified by food intake.
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